Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells

10 Feb 2012

Abstract excerpt

An acquired mutation (T790M) in the epidermal growth factor receptor (EGFR) accounts for half of all relapses in non-small cell lung cancer (NSCLC) patients who initially respond to EGFR kinase inhibitors. In this study, we demonstrated for the first time that EGFR-T790M interacts with the cytoskeletal components, myosin heavy chain 9 (MYH9) and β-actin, in the nucleus of H1975 cells carrying the T790M-mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22366308
DOI: 10.1016/j.molonc.2012.02.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cellsPMID 22366308Read ↗

Non-Muscle Myosin II A: Friend or Foe in Cancer?Semantic proximity Read ↗

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.Semantic proximity Read ↗

MYH9: A key protein involved in tumor progression and virus-related diseases.Semantic proximity Read ↗

LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial-Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway.Semantic proximity Read ↗

Exploring the nexus between MYH9 and tumors: novel insights and new therapeutic opportunitiesSemantic proximity Read ↗

Myosin Heavy Chain 9: Oncogene or Tumor Suppressor Gene?Semantic proximity Read ↗

Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.Semantic proximity Read ↗

Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.Semantic proximity Read ↗

Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non-Small Cell Lung Cancer Cells.Semantic proximity Read ↗

Molecular Pathways: New Signaling Considerations When Targeting Cytoskeletal Balance to Reduce Tumor GrowthSemantic proximity Read ↗

Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells.Semantic proximity Read ↗

Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.